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1) To calculate the actual RTU rates in NSW & ACT (2004-06) directly 
from patient treatment records with special emphasis on the effect of 
geographic variation on RTU. 
2) To identify factors affecting RTU 
Materials and Methods: Radiotherapy treatment data were collected 
from all 17 radiotherapy departments (RTD) in NSW and ACT for the 
period January 2004-June 2007. Through Center for Health Record 
Linkage, the radiotherapy data and Central Cancer Registries (CCR) 
records in NSW & ACT were linked. . All patients' residential addresses 
were geocoded. A Geographic Information System (GIS) software was 
used to calculate the road distance between patients' residential 
address and the closest RTD. Patients were excluded from the study if 
their nearest RTD was outside NSW or ACT. 
Results: The overall raw RTU rate in NSW and ACT (2004-06) was 32%. 
After data linkage with CCR records, the overall RTU rate was 24% for 
unique patients diagnosed and received radiotherapy within the study 
period. Excluding patients at the borders with other States, the RTU 
rate was 26%. The RTU rates decreased with increasing distance from 
patient residence to the nearest radiotherapy facility (p <0.0001). 
RTU ranged from 27% for those who lived less than 50 km to 19% for 
those who lived 400+ Km from the nearest RTD. Older patients were 
less likely to receive RT than younger ones (p<0.001) and female 
younger patients were more likely to receive RT than younger males 
(p<0.001). Our study did not show a correlation between receiving RT 
and the socioeconomic status of patients using Index of Relative 
Socioeconomic Disadvantage quintiles.  
Conclusions: This is the first study to use data linkage to match 
radiotherapy treatment data received from all RTD to all CCR records 
in NSW and ACT. It is also the first study to calculate the road 
distance between patient residence and the nearest radiotherapy 
facility. There was a statistically significant difference in radiotherapy 
access based on road distance. 
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Purpose/Objective: To estimate the expected comparative 
costs/Quality Adjusted Life Year (QALY) gained of the guideline 
recommended treatments Active Surveillance (AS), Radical 
Prostatectomy (RP), Brachytherapy (BT), EBRT and appropriate 
combinations hereof incl. Androgen Deprivation Therapy (ADT) in 
patients with low, intermediate or high risk prostate cancer over a 
time horizon of 10 years from an UK-NHS cost perspective. 
Materials and Methods: A decision analytic model was developed 
considering survival, health related quality of life and costs associated 
with 1) initial treatment and 2) management of relapse, local 
recurrence, metastasis, and 3) treatment-associated complications 
and morbidities. The wide range of appropriate treatments to be 
compared for low, intermediate and high risk prostate cancers were 
based on NICE, EAU, AUA and NCCN guidelines. Survival, relapse, 
recurrence, metastasis and complication rates, as well as health-
related quality of life and cost data were based on systematic reviews 
of the published literature and expert opinions where required. 
Probabilistic sensitivity analysis, using 10000 Monte Carlo simulations, 
quantified the joint decision uncertainty surrounding model outcomes 
at the prevailing threshold of £20k-30k/QALY. 
Results: In low risk prostate cancer, AS has the highest probability for 
being cost-effective (C/E), i.e. 70%. When AS is unacceptable to a 
patient, BT dominates EBRT by generating more QALYs/patient 
(+0,06) at lower cost (-£14k) over 10-years. EBRT is C/Evs. RP as 
shown by the incremental C/E ratio of £7k/QALY which is far below 
the WTP threshold. In intermediate risk, EBRT+BT is the dominating 
treatment (5,02QALYs at £14.7k; 65% probability C/E), followed by BT 
as monotherapy (4,98QALYs at £16.9k; 35% probability C/E). RP 
generates the lowest QALYs at relatively high costs (4,06 QALYs, 
£28.8k). In high risk, all mono and combination radiation treatments 
dominate RP which generates 3,96 QALYs at £35.4 over 10 
years/patient. EBRT+BT (4,7 QALYs, £35.1k) is most C/E compared to 
monoradiation treatments by generating more QALYs at only slightly 
higher total costs. BT (4,65 QALYs, £32.5k) dominates EBRT (4,62 
QALYs, £32.5k) and EBRT+ADT(4,47 QALYs, £37.7k). 
Conclusions: Across risk groups, RP is likely to perform worse than 
radiation treatments in terms of expected costs/QALY. In 
intermediate and high risk prostate cancer, EBRT+BT is expected to 
provide highest QALYs at acceptable or lower cost than monoradiation 
treatments and RP. In low risk prostate cancer, AS is preferred in 
terms of QALYs, while BT dominates EBRT and RP in terms of 
costs/QALYs.  
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Purpose/Objective: In the framework of a feasibility study for a 
hadron therapy centre in Belgium, cost calculations are performed by 
means of two separate models, with the aim to determine the 
treatment cost per patient and to estimate the need for 
reimbursement for different technical solutions. 
Materials and Methods: The Business Model (BM) analyses the 
financial implications of setting up a facility over time, taking into 
account all costs incurred from the preparatory phase, first 
investment and commissioning, over the ramp-up period where the 
centre starts to accrue patients, until operation at full capacity and 
beyond. The Activity-Based Costing (ABC) model calculates the costs 
for a centre in a specific year corresponding to a steady state of 
operation. Both models analyse private financing compared to 
financing with public investment to cover investment costs. Three 
different technical solutions are considered, all with two treatment 
rooms: a combined proton/carbon ion centre, a dedicated carbon ion 
and a dedicated proton centre. Input parameters for both models 
(investment and operational costs, patient population, fractionation 
schedules and time slots) are derived from discussions with 
international experts and literature. 
Results: The total investment cost ranges from 51,5 M€ for a 
dedicated proton centre up to 101,5 M€ for a combined centre. The 
annual operational cost is influenced by the financing system and 
ranges from 10,0 M€ (proton centre, public financing) up to 24,8 M€ 
(combined centre, private financing). 
Table 1 summarizes the required reimbursement per patient 
necessary to yield a positive cumulative net cash flow after 16 years 
of operation using the BM, and the average cost per patient and cost 
per type of treatment and fraction using the ABC model. Costs are 
expressed in Euro for the year 2012.  
 
 
As they disregard the impact of inflation, the costs calculated with 
ABC are lower than the required reimbursement based on the BM.  
Sensitivity analyses show that the required reimbursement for 
privately financed centres is highly sensitive to the delay in 
commissioning and to the interest rate. Uncertainties in investment 
cost have a greater impact on treatment cost and required 
reimbursement than changes in personnel costs. Operating scenario, 
product mix and fractionation schedules have a significant impact on 
the cost per treatment and per fraction. 
Conclusions: To align costs to European reimbursement rates, our 
calculations suggest that the financially most attractive option for 
Belgium is a dedicated carbon ion centre with public financing. The 
choice however also depends on the clinical indications and the socio-
political context. 
   
  
